Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: A report from the African American Study of Kidney Disease (AASK) Trial

被引:203
作者
Fogo, A
Breyer, JA
Smith, MC
Cleveland, WH
Agodoa, L
Kirk, KA
Glassock, R
Faulkner, M
Kopple, JD
Massry, SG
Grim, C
Randall, OS
Toto, RD
Whelton, P
Wright, JT
机构
[1] VANDERBILT UNIV, MED CTR,DIV NEPHROL, NASHVILLE, TN 37232 USA
[2] CASE WESTERN RESERVE UNIV, DEPT MED, CLEVELAND, OH 44106 USA
[3] MOREHOUSE SCH MED, ATLANTA, GA 30310 USA
[4] NIDDK, DIV KIDNEY UROL & HEMATOL DIS, BETHESDA, MD USA
[5] UNIV ALABAMA, BIRMINGHAM, AL USA
[6] UNIV KENTUCKY, DEPT MED, LEXINGTON, KY 40506 USA
关键词
D O I
10.1038/ki.1997.29
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
African Americans have excess hypertension and end-stage renal disease presumed due to hypertension compared to Caucasians. The AASK was designed to examine the impact of antihypertensive therapies and two levels of blood pressure control on the rate of decline of GFR in African Americans with presumed hypertensive renal disease. During the pilot phase of the trial, eligible participants were requested to undergo renal biopsy to assess the underlying lesions in this population. Eighty-eight hypertensive (diastolic BP > 95 mm Hg) non-diabetic African American patients between the ages of 18 to 70 years, with GFR between 25 to 70 ml/min/1.73 m(2) and without marked proteinuria were assessed for possible renal biopsy. Forty-three patients did not undergo renal biopsy due to refusal or contraindications. Adequate renal biopsies were obtained in 39 of the remaining 46 patients. Biopsy findings were analyzed and then compared to clinical parameters. The 39 patients studied, 29 men and 10 women, were on average 53.0 +/- 11.0 years old, and had a MAP of 109 +/- 15 mm Hg and GFR 51.7 +/- 13.6 ml/min/1.73 m(2) (not significantly different from nonbiopsied patients). Thirty-eight of these 39 biopsies showed arteriosclerosis and/or arteriolosclerosis, severity on average 1.5 +/- 0.9 and 1.5 +/- 0.8, respectively on a 0 to 3+ scale. Interstitial fibrosis was moderate, 1.3 +/- 0.9 (0 to 3+ scale). Segmental glomerulosclerosis was present in five biopsies, and in one patient, biopsy and clinical findings were consistent with idiopathic focal segmental glomerulosclerosis. Additional lesions included mesangiopathic glomerulonephritis in one patient, basement membrane thickening suggestive of diabetic nephropathy in one, and cholesterol emboli in two cases. Arteriolar and arterial sclerosis were tightly linked, and correlated with interstitial fibrosis and the reciprocal of scrum creatinine. Global glomerulosclerosis was extensive, involving on average 43 +/- 26% of glomeruli. The extent of this lesion did not correlate with degree of arteriolar or arterial thickening, but did correlate with systolic blood pressure (P = 0.0174), the reciprocal of serum creatinine (P = 0.0009), serum cholesterol (P = 0.0129) and interstitial fibrosis (P < 0.0001). These data underscore that renal biopsies in non-diabetic hypertensive African-Americans with mild to moderate renal insufficiently in the absence of marked proteinuria are overwhelmingly likely to show renal vascular lesions consistent with the clinical diagnosis of hypertensive nephrosclerosis.
引用
收藏
页码:244 / 252
页数:9
相关论文
共 62 条
[51]   ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR MODULATES GLOMERULAR FUNCTION AND STRUCTURE BY DISTINCT MECHANISMS [J].
TANAKA, R ;
KON, V ;
YOSHIOKA, T ;
ICHIKAWA, I ;
FOGO, A .
KIDNEY INTERNATIONAL, 1994, 45 (02) :537-543
[52]  
TEIO KK, 1995, BRIT MED J, V311, P76
[53]  
TRACY RE, 1993, AM J HYPERTENS, V6, P185
[54]   ENHANCED PRESSOR-RESPONSE TO ANGIOTENSIN-I IN NORMOTENSIVE MEN WITH THE DELETION GENOTYPE (DD) FOR ANGIOTENSIN-CONVERTING ENZYME [J].
UEDA, S ;
ELLIOTT, HL ;
MORTON, JJ ;
CONNELL, JMC .
HYPERTENSION, 1995, 25 (06) :1266-1269
[55]  
*US REN DAT SYST, 1995, USRDS 1995 ANN DAT R
[56]  
*US VIT HLTH STAT, 1986, NAT HLTH SURV SER, V11, P48
[57]   RENAL-FUNCTION CHANGE IN HYPERTENSIVE MEMBERS OF THE MULTIPLE RISK FACTOR INTERVENTION TRIAL - RACIAL AND TREATMENT EFFECTS [J].
WALKER, WG ;
NEATON, JD ;
CUTLER, JA ;
NEUWIRTH, R ;
COHEN, JD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 268 (21) :3085-3091
[58]  
WHELTON P, 1994, J AM SOC NEPHROL, V5, P570
[59]   DOES RACIAL VARIATION IN RISK-FACTORS EXPLAIN BLACK-WHITE DIFFERENCES IN THE INCIDENCE OF HYPERTENSIVE END-STAGE RENAL-DISEASE [J].
WHITTLE, JC ;
WHELTON, PK ;
SEIDLER, AJ ;
KLAG, MJ .
ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (07) :1359-1364
[60]  
WRIGHT JT, 1994, J AM SOC NEPHROL, V5, P570